GPN3 Inhibitors
Chemical inhibitors of GPN3 include a variety of compounds that target cellular kinases, particularly those involved in the regulation of the cell cycle. Alsterpaullone, Roscovitine, Olomoucine, Purvalanol A, Flavopiridol, and Indirubin-3'-monoxime, for instance, are inhibitors of cyclin-dependent kinases (CDKs), which are essential for the cell cycle progression. By impeding these kinases, these inhibitors can arrest the cell cycle at specific checkpoints, effectively leading to a decrease in GPN3 activity, which is associated with nucleotide metabolism and transport, particularly during phases of the cell cycle where its activity is crucial. The blockade of these kinases results in a downregulation of the cellular processes that require GPN3 function, thereby inhibiting the protein indirectly.
Moreover, compounds like 5-Iodotubercidin disrupt cellular adenosine kinase activity, which can result in altered ATP levels. Since GPN3 is involved in energy-dependent processes within the cell, disturbances in ATP levels can indirectly inhibit its function. Other CDK inhibitors such as Palbociclib, Dinaciclib, Milciclib, Ribociclib, and Abemaciclib exhibit their inhibitory effects by halting the cell cycle, particularly at the G1-S transition. This arrest prevents the cell from entering the cell cycle phases that necessitate GPN3's role, reducing the functional demand for GPN3 and leading to its inhibition. These chemicals, through their targeted action on specific cell cycle kinases, manage to indirectly inhibit GPN3 by stalling the cellular processes that it is implicated in, thus preventing the normal functioning of the protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits CDKs which are necessary for cell cycle progression. Inhibition of CDKs can indirectly suppress GPN3 activity by halting the cell cycle phases where GPN3 is active. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine targets CDKs, including CDK1, CDK2, and CDK5. GPN3, being implicated in nucleotide metabolism and transport, can be functionally inhibited by disrupting the cell cycle. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
As a CDK inhibitor, Olomoucine impedes cell cycle kinases. A stalled cell cycle can lead to a decrease in the activity of GPN3, which is involved in specific cell cycle-dependent processes. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
By inhibiting CDKs, Purvalanol A can halt cellular division processes, indirectly leading to a reduction in GPN3 activity that is associated with cell cycle progression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol broadly inhibits CDKs, effectively blocking the cell cycle. This broad inhibition can lead to a functional suppression of GPN3 by reducing the need for its associated activities. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This chemical is a CDK inhibitor and would disrupt GPN3's role in the cell cycle by inhibiting the kinases that regulate cell cycle checkpoints where GPN3 might be involved. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
An adenosine kinase inhibitor, 5-Iodotubercidin, could inhibit GPN3 by disrupting cellular ATP levels, indirectly affecting the energy-dependent processes GPN3 is involved in. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib selectively inhibits CDK4/6, arresting the G1-S phase transition. GPN3, which may indirectly be involved in the progression of the cell cycle, would be functionally inhibited. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib inhibits multiple CDKs, potentially leading to a decrease in GPN3 activity by halting cell cycle progression and the processes that GPN3 is involved in. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets various kinases involved in cell proliferation. Hindering these pathways can indirectly inhibit GPN3 by suppressing the cellular demand for its activity. | ||||||